ICON Public (NASDAQ:ICLR) Price Target Cut to $240.00 by Analysts at Barclays

ICON Public (NASDAQ:ICLR) had its target price trimmed by Barclays from $275.00 to $240.00 in a research note published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

ICLR has been the topic of several other reports. TD Cowen reduced their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group reduced their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Truist Financial cut their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Citigroup lowered their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and an average target price of $281.00.

ICON Public Stock Performance

NASDAQ:ICLR opened at $201.39 on Friday. The company’s 50-day moving average is $202.90 and its two-hundred day moving average is $245.37. ICON Public has a 1-year low of $181.51 and a 1-year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The firm has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.76 and a beta of 1.19.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a return on equity of 11.79% and a net margin of 9.56%. Analysts forecast that ICON Public will post 13.38 EPS for the current year.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently made changes to their positions in ICLR. Sierra Ocean LLC acquired a new stake in shares of ICON Public in the 4th quarter valued at about $29,000. Park Place Capital Corp boosted its holdings in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the period. Private Trust Co. NA grew its position in shares of ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. Finally, First Horizon Advisors Inc. raised its position in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.